Ms Caroline Boulliat | Immunology Franchise Head of Biosimilars for Europe, Middle East and Africa Hospira
Responsible for Launching INFLECTRA, (first 'Mab' biosimilar ) in the EMEA region Potential Value: 2 Billions. In charge of commercial / Marketing / Market Access activities